Category Archives: Global News Feed

STEM Animal Health Appoints New President and CEO

By Global News Feed

WINNIPEG, Manitoba, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech”) today announced that Kevin Cole will assume the role of President and CEO of STEM Animal Health Inc. (“STEM”), a subsidiary created from the recently formed joint venture with UK-based international veterinary products company, Animalcare Group PLC (AIM:ANCR) (“Animalcare”).

Read the rest here:
STEM Animal Health Appoints New President and CEO

Novavax Appoints Leadership Team to Advance NanoFlu through Regulatory Licensure

By Global News Feed

GAITHERSBURG, Md., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the formation of a leadership team to advance NanoFlu to regulatory licensure and the promotion of Russell (Rip) Wilson, J.D./M.B.A., to Executive Vice President and the newly-created role of NanoFlu™ General Manager. Mr. Wilson will focus exclusively on leading efforts to advance NanoFlu, the company’s influenza vaccine candidate, through global licensure, as well as the exploration of a combined influenza/COVID-19 vaccine that could be used in a post-pandemic setting. Novavax announced results of its successful NanoFlu pivotal Phase 3 clinical trial earlier this year and intends to seek regulatory approval from the U.S. Food and Drug Administration (FDA) under the accelerated approval pathway previously granted to the company.

Continued here:
Novavax Appoints Leadership Team to Advance NanoFlu through Regulatory Licensure

PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation

By Global News Feed

CRANBURY, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., (Nasdaq: PMVP) a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate PC14586, for the treatment of cancer patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation. There are currently no FDA-approved medicines that target the p53 Y220C mutation.

See more here:
PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation

Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference

By Global News Feed

WARMINSTER, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright HBV Mini-Conference on Tuesday, October 20, 2020 at 10:00 am ET.

Link:
Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference

Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference

By Global News Feed

DUBLIN, Ireland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, today announced that its executive team will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference taking place September 14 – 16, 2020.

Read more here:
Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual…

By Global News Feed

LEXINGTON, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced results from preclinical studies of KER-012 at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting Virtual Event held September 11-15, 2020.

Excerpt from:
Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual...

Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial

By Global News Feed

NEW YORK and MAINZ, GERMANY, Sept. 12, 2020 (GLOBE NEWSWIRE) --  NEW YORK and MAINZ, GERMANY, September 12 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced today that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations.

See the original post here:
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial

Adamas Announces New Employment Inducement Grant

By Global News Feed

EMERYVILLE, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 269,250 shares of the company’s common stock, at a per share exercise price of $5.12, the closing trading price on September 8, and restricted stock units to acquire 2,125 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

Read more:
Adamas Announces New Employment Inducement Grant